Parkman Healthcare Partners LLC Supernus Pharmaceuticals, Inc. Transaction History

Parkman Healthcare Partners LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $426,113 - $556,648	-18,755 Reduced 13.57%	119,417 $3.46 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $1.43 Million - $1.71 Million	-52,007 Reduced 27.35%	138,172 $3.81 Million
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $1.74 Million - $2.26 Million	58,301 Added 44.21%	190,179 $5.72 Million
Q1 2023 May 12, 2023	BUY	$34.93 - $42.03 $1.29 Million - $1.55 Million	36,972 Added 38.96%	131,878 $4.78 Million
Q4 2022 Feb 13, 2023	BUY	$31.09 - $37.88 $161,574 - $196,862	5,197 Added 5.79%	94,906 $3.39 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $30,258 - $37,215	1,051 Added 1.19%	89,709 $3.04 Million
Q2 2022 Aug 12, 2022	SELL	$25.33 - $34.25 $514,097 - $695,138	-20,296 Reduced 18.63%	88,658 $2.56 Million
Q1 2022 May 13, 2022	BUY	$28.51 - $32.9 $120,882 - $139,496	4,240 Added 4.05%	108,954 $3.52 Million
Q4 2021 Feb 11, 2022	BUY	$26.37 - $34.22 $113,364 - $147,111	4,299 Added 4.28%	104,714 $3.05 Million
Q2 2021 Aug 13, 2021	BUY	$26.72 - $33.19 $2.68 Million - $3.33 Million	100,415 New	100,415 $3.09 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.